Tags

Type your tag names separated by a space and hit enter

Brofaromine (CGP 11 305 A) in treatment of depression: biological estimation of plasma concentrations.
Pharmacopsychiatry. 1990 May; 23(3):131-4.P

Abstract

In an open clinical trial, 13 depressives were treated with the reversible and selective type-A monoamine oxidase (MAO)-inhibitor brofaromine (CGP 11 305 A), the inhibitory potency of deproteinated plasma on a crude MAO preparation from human placenta was measured as a parameter for plasma brofaromine and possibly active metabolites of brofaromine. Patients significantly (p less than 0.01) improved under brofaromine. There were, however, no significant differences in plasma MAO-inhibitory potency between responders (improvement greater than 50%; n = 5) and nonresponders and no correlations with the change from baseline of the total Hamilton Depression Score (HAMD) or with changes of sleep (change from baseline of the HAMD sleep items). MAO-inhibitory potency significantly (p less than 0.05) increased parallel to the increase of the dosage from 50 mg b.i.d. to t.i.d., confirming the validity of this technique. The biological assay applied is a simple and reliable alternative when estimating the plasma concentrations of brofaromine and, possibly, other reversible MAO inhibitors.

Authors+Show Affiliations

Department of Psychiatry and Clinical Neurochemistry, School of Medicine, University of Würzburg, F.R.G.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

2374771

Citation

Fritze, J, et al. "Brofaromine (CGP 11 305 A) in Treatment of Depression: Biological Estimation of Plasma Concentrations." Pharmacopsychiatry, vol. 23, no. 3, 1990, pp. 131-4.
Fritze J, Becker T, Ziegler V, et al. Brofaromine (CGP 11 305 A) in treatment of depression: biological estimation of plasma concentrations. Pharmacopsychiatry. 1990;23(3):131-4.
Fritze, J., Becker, T., Ziegler, V., Laux, G., & Riederer, P. (1990). Brofaromine (CGP 11 305 A) in treatment of depression: biological estimation of plasma concentrations. Pharmacopsychiatry, 23(3), 131-4.
Fritze J, et al. Brofaromine (CGP 11 305 A) in Treatment of Depression: Biological Estimation of Plasma Concentrations. Pharmacopsychiatry. 1990;23(3):131-4. PubMed PMID: 2374771.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Brofaromine (CGP 11 305 A) in treatment of depression: biological estimation of plasma concentrations. AU - Fritze,J, AU - Becker,T, AU - Ziegler,V, AU - Laux,G, AU - Riederer,P, PY - 1990/5/1/pubmed PY - 1990/5/1/medline PY - 1990/5/1/entrez SP - 131 EP - 4 JF - Pharmacopsychiatry JO - Pharmacopsychiatry VL - 23 IS - 3 N2 - In an open clinical trial, 13 depressives were treated with the reversible and selective type-A monoamine oxidase (MAO)-inhibitor brofaromine (CGP 11 305 A), the inhibitory potency of deproteinated plasma on a crude MAO preparation from human placenta was measured as a parameter for plasma brofaromine and possibly active metabolites of brofaromine. Patients significantly (p less than 0.01) improved under brofaromine. There were, however, no significant differences in plasma MAO-inhibitory potency between responders (improvement greater than 50%; n = 5) and nonresponders and no correlations with the change from baseline of the total Hamilton Depression Score (HAMD) or with changes of sleep (change from baseline of the HAMD sleep items). MAO-inhibitory potency significantly (p less than 0.05) increased parallel to the increase of the dosage from 50 mg b.i.d. to t.i.d., confirming the validity of this technique. The biological assay applied is a simple and reliable alternative when estimating the plasma concentrations of brofaromine and, possibly, other reversible MAO inhibitors. SN - 0176-3679 UR - https://www.unboundmedicine.com/medline/citation/2374771/Brofaromine__CGP_11_305_A__in_treatment_of_depression:_biological_estimation_of_plasma_concentrations_ L2 - http://www.thieme-connect.com/DOI/DOI?10.1055/s-2007-1014495 DB - PRIME DP - Unbound Medicine ER -